Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8086 to 8100 of 9128 results

  1. Suspected cancer (QS124)

    April 2026: We have withdrawn this quality standard following the launch of the updated NICE guideline on suspected cancer: recognition and referral. An updated NICE quality standard for suspected cancer is being developed.  For any queries, please contact qualitystandards@nice.org.uk.

    Withdrawn quality standard

  2. Unilateral MRI-guided focused ultrasound thalamotomy for moderate to severe tremor in Parkinson's disease (IPG606)

    This guidance has been updated and replaced by NICE HealthTech guidance 733.

    Withdrawn guidance

  3. Sodium zirconium cyclosilicate for treating hyperkalaemia (TA599)

    This guidance has been updated and replaced by NICE's technology appraisal guidance on sodium zirconium cyclosilicate for treating hyperkalaemia (TA1148).

    Withdrawn guidance

  4. Ripretinib for treating advanced gastrointestinal stromal tumour after 3 or more treatments (TA881)

    This guidance has been updated and replaced by NICE technology appraisal guidance on ripretinib for treating advanced gastrointestinal stromal tumours after 3 or more kinase inhibitors (TA1146).

    Withdrawn guidance

  5. L-Dex U400 for lymphoedema after breast cancer treatment (MIB111)

    April 2026: This Medtech innovation briefing has been withdrawn because the L-Dex U400 device is no longer available in the UK.

    Withdrawn advice

  6. Synthetic cartilage implant insertion for first metatarsophalangeal joint osteoarthritis (hallux rigidus) (HTG627)

    This guidance has been withdrawn because Cartiva Synthetic Cartilage Implant (SCI) has been recalled, and the evidence for this guidance was based solely on Cartiva SCI. More information is available in the field safety notice issued by Stryker. Surgeons are advised not to implant this device, to return any unused devices to Stryker and to consider reviewing any patients who have had Cartiva SCI. NICE will consider issuing new guidance on synthetic cartilage implant insertion for first metatarsophalangeal joint osteoarthritis (hallux rigidus) if evidence using an appropriately CE-marked device becomes available.

    HealthTech guidance
    Published
    1 June 2022

  7. Leadless cardiac pacemaker implantation for bradyarrhythmias (HTG484)

    This guidance has been updated and replaced by NICE HealthTech guidance 770.

    HealthTech guidance
    Published
    29 August 2018

  8. Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer (TA1108)

    This guidance has been updated and replaced by NICE technology appraisal guidance on cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer (TA1165).

    Withdrawn guidance

  9. Anaphylaxis: assessment and referral after emergency treatment (CG134)

    This guideline has been updated and replaced by NICE guideline NG258.

    Withdrawn guideline

  10. Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (terminated appraisal) (TA987)

    This guidance has been updated and replaced by NICE's technology appraisal guidance 1159 (TA1159).

    Withdrawn guidance

  11. Nusinersen for treating spinal muscular atrophy (TA588)

    This guidance has been updated and replaced by NICE's technology appraisal guidance on nusinersen and risdiplam for treating spinal muscular atrophy (TA1162).

    Withdrawn guidance

  12. Risdiplam for treating spinal muscular atrophy (TA755)

    This guidance has been updated and replaced by NICE's technology appraisal guidance on nusinersen and risdiplam for treating spinal muscular atrophy (TA1162).

    Withdrawn guidance

  13. Cemiplimab for treating recurrent or metastatic cervical cancer (terminated appraisal) (TA901)

    This guidance has been updated and replaced by NICE technology appraisal guidance on cemiplimab for treating recurrent or metastatic cervical cancer that has progressed on or after platinum-based chemotherapy (TA1174).

    Withdrawn guidance

  14. Sabatolimab with azacitidine for untreated high-risk myelodysplastic syndromes [ID3996]

    Discontinued Reference number: GID-TA10897

    Technology appraisal guidance
    Discontinued

  15. Venetoclax with dexamethasone for treating relapsed or refractory t(11;14)-positive multiple myeloma after lenalidomide and a proteasome inhibitor [ID4040]

    Discontinued Reference number: GID-TA10926

    Technology appraisal guidance
    Discontinued